Stifel reiterates USD 190.00 target for Glaukos stock, 15.26 percent above price

Published on 10/17/2026 at 21:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results are due October 28, 2026. Glaukos stock was last at USD 164.84 on October 16, 2026, down 0.46 percent versus the NYSE prior close.

Stifel target and October date

Stifel reiterated a USD 190.00 target for Glaukos on October 16, 2026, 15.26 percent above the last price.
Glaukos plans to release third-quarter results after market close on October 28, 2026.
Glaukos stock was last at USD 164.84 on October 16, 2026 at 4:00 p.m. EDT, down 0.46 percent versus the NYSE prior close.
Glaukos had a USD 9.7 billion market capitalization and a negative trailing P/E ratio of 50.72 on October 16, 2026.

GKOS, US3773221029, Illustration mit AI erstellt.

Stifel reiterated a Buy rating and a USD 190.00 price target for Glaukos on October 16, 2026, according to Investing.com. The target stands 15.26 percent above the last NYSE price of USD 164.84 on October 16, 2026. Glaukos was last at USD 164.84 at 4:00 p.m. EDT, down 0.46 percent from the prior close of USD 165.60.

October 28 brings the next date

Glaukos plans to release third-quarter 2026 financial results after the market close on October 28, 2026, with management scheduled to discuss the figures at 4:30 p.m. ET. BioSpace carried the company release, which describes Glaukos as an ophthalmic pharmaceutical and medical technology company focused on glaucoma, corneal disorders, and retinal diseases.

Price sits below the yearly high

The last NYSE price of USD 164.84 was 13.98 percent below the 52-week high of USD 191.62 and 125.31 percent above the low of USD 73.16, both dated October 16, 2026. The session range was USD 163.13 to USD 167.28, while volume reached 985,416 shares against an average of 864,189, a 14.03 percent increase.

That placement gives the analyst target a clear numerical hurdle. The USD 190.00 target is 15.26 percent above the last price, while the 52-week high is 16.25 percent higher than the last price. The figures describe distance rather than a forecast.

What does the target imply?

Glaukos had a market capitalization of USD 9.7 billion and a trailing price-to-earnings ratio of minus 50.72 on October 16, 2026. The company paid no trailing dividend yield in the quoted figures. Stifel's USD 190.00 target therefore sits above both the latest price and the stock's reported trailing valuation level, without changing the underlying earnings risk.

The upcoming October 28 release is the next scheduled point at which investors can compare the company's operating progress with its current valuation. The last quarterly discussion highlighted product development and commercialization as important drivers, while the next report will provide the next dated operating checkpoint.

Price and valuation

Glaukos was last at USD 164.84 on the NYSE on October 16, 2026 at 4:00 p.m. EDT, down 0.46 percent versus the NYSE prior close of USD 165.60. The stock's 52-week range was USD 73.16 to USD 191.62, and market capitalization stood at USD 9.7 billion.